The effect of protease inhibitors on weight and body composition in HIV-infected patients.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

The effect of protease inhibitors on weight and body composition in HIV-infected patients.

AIDS. 1998 Sep 10;12(13):1645-51. Unique Identifier : AIDSLINE MED/98435813
Silva M; Skolnik PR; Gorbach SL; Spiegelman D; Wilson IB; Fernandez-DiFranco MG; Knox TA; Department of Community Health, Tufts University School of; Medicine, and the New England Medical Center Hospitals, Boston,; Massachusetts 02111, USA.

Abstract: OBJECTIVES: To determine the nutritional changes that occur in HIV-infected patients receiving protease inhibitor (PI) therapy and to determine the effects of PI treatment on physical functioning and health perceptions in patients with HIV infection. DESIGN: Longitudinal data analysis of 38 patients from a large Nutrition and HIV cohort. METHODS: Patients were included if they had started PI therapy after enrollment in the cohort, if they had taken the drug for at least 4 months without interruption and if data on weight, body composition and viral loads were available. RESULTS: Mean person-months of follow-up was 8.1 months before and 12.2 months after PI treatment. Weight (1.54 kg, P < 0.0001), body mass index (0.50 kg/m2, P < 0.0001), physical functioning (8.52 points, P = 0.0006) and current health perception (6.7 points, P = 0.01) increased significantly, and the daily caloric intake increase was close to significance (915.5 kJ/day, P = 0.06), after treatment with PI. Lean body mass did not change. Patients who responded to PI therapy with decreased viral load (n = 28) had significantly greater weight gain per month than non-responders. CONCLUSIONS: PI therapy of HIV infection is associated with weight gain and improvement in quality of life indices. The weight gain is mainly in fat mass, with no change in lean body mass (skeletal muscle). Optimal therapy of HIV-infected patients with weight loss may require highly active antiretroviral therapy combined with an anabolic stimulus such as exercise, anabolic steroids or human growth hormone.

Keywords: CLINICAL TRIAL JOURNAL ARTICLE MULTICENTER STUDY Adult Body Composition/*DRUG EFFECTS Body Weight/*DRUG EFFECTS Cohort Studies Drug Therapy, Combination Female Human HIV Infections/*DRUG THERAPY HIV Protease Inhibitors/*THERAPEUTIC USE Indinavir/THERAPEUTIC USE Longitudinal Studies Male Middle Age Nutritional Status/*DRUG EFFECTS Ritonavir/THERAPEUTIC USE Saquinavir/THERAPEUTIC USE Support, U.S. Gov't, P.H.S. Viral Load
990228
A9920965

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .